Patients were randomly assigned ( @:@ ) by use of a central interactive voice response system using a block randomisation schedule ( block size four ) stratified by hormone receptor status , first-line progression-free survival , selected chemotherapy , and lactate dehydrogenase concentration , to receive second-line single-agent chemotherapy either alone or with bevacizumab ( @ mg/kg every @ weeks or @ mg/kg every @ weeks ) .